Few analysts foresaw the disappointing results and profit forecast that sent Boston Scientific Corp.’s shares plummeting nearly 20% this week. Even fewer have given up on their bullish calls since. It ...

Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor expectations. This response was ...

Despite growing sales and adjusted EPS by 16% and 14% in Q4 -- easily beating Wall Street’s estimates -- Boston Scientific stock dropped 18% on Wednesday due to “weak” guidance. More specifically, the ...

Boston Scientific grew sales and adjusted earnings per share by 16% and 14% in the fourth quarter. However, the company's guidance underwhelmed the market. Ultimately, Boston Scientific's earnings ...

Boston Scientific’s fourth-quarter profit and sales climbed but the medical-device maker issued a soft forecast for the year, sending shares down in premarket trading. The company logged earnings of ...

Shares of leading cardiovascular and medsurg (medical-surgical) technologies provider Boston Scientific (NYSE: BSX) are down 16% as of noon ET on Wednesday, following its fourth-quarter earnings ...

Add Yahoo as a preferred source to see more of our stories on Google. Boston Scientific's headquarters is in Marlborough, Massachusetts. (Courtesy of Boston Scientific) This story was originally ...

During Boston Scientific chief executive Mike Mahoney’s 13-year tenure, he has presided over more than 40 acquisitions so far. But this one is different, at least by size: Mahoney on Thursday unveiled ...

Boston Scientific is spending $14.5 billion in cash and stock to buy Penumbra, another medical-device maker that makes products used in minimally invasive procedures to treat conditions such as blood ...

Good morning, and welcome to the Boston Scientific Investor Update. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Lauren Tengler, ...

Penumbra expected to generate $1.4 bln in 2025 sales; shares surge 12% Transaction values Penumbra at $374 per share, 19.3% premium to last close Penumbra CEO Adam Elsesser to join Boston Scientific's ...

Boston Scientific said on Thursday it will buy ⁠medtech firm Penumbra in a deal valued at about $14.5 billion to expand its portfolio of cardiovascular devices, in the largest acquisition by the ...